psychedelics-investing Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service
psychedelics-investing Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
psychedelics-investing Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis Technology to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
psychedelics-investing Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
psychedelics-investing Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
psychedelics-investing Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
psychedelics-investing Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist
psychedelics-investing Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
psychedelics-investing Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder
